Table 2.

Clinical evidence of SGLT2i's atheroprotective effects.

Drugs	Type of study	Characteristics of patients (number)	Treatment	Possible atheroprotective effects	References
Empaglifozin	Prospective, open-label observational	T2DM (15)	24-week empagliflozin 10 mg vs. baseline	↓ CRP/hs-CRP	(52)
Canaglifozin	Prospective, open-label, randomized controlled trial	T2DM, HF (35)	12 month CRP canagliflozin 100 mg vs. baseline	↓ CRP/hs-CRP	(53)
Dapaglifozin	Prospective, open-label, blinded endpoint, randomized	T2DM (72)	16 week dapagliflozin 5 mg/day + Metformin 750 mg/day vs. Metformin 1,500 mg/day	↓ 8-OHdG	(55)

CRP, c-reactive protein; TNF α, tumor factor alpha necrosis; IL6, interleukin-6; hsCRP, high-sensitivity c-reactive protein; 8-OhdG, 8-Hydroxy-20–deoxyguanosine; T2DM, type 2 diabetes mellitus.